INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...
WESTLAKE VILLAGE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...
NEW YORK — Topical antifungals should no longer be considered a first-line therapy for seborrheic dermatitis for two reasons: Topical anti-inflammatories have replaced them, and rates of ...
Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children ...
This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...
Seborrheic dermatitis is positively associated with a range of epithelial barrier diseases, including dermatologic, respiratory, gastrointestinal, and ocular diseases. Seborrheic dermatitis is ...
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results